Alnylam Pharmaceuticals (ALNY) – Analysts’ Recent Ratings Changes

Alnylam Pharmaceuticals (NASDAQ: ALNY) has recently received a number of price target changes and ratings updates:

• 11/12/2024 – Alnylam Pharmaceuticals was downgraded by analysts at Wolfe Research from a “peer perform” rating to an “underperform” rating.
• 11/4/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its price target raised by analysts at Scotiabank from $305.00 to $310.00. They now have a “sector outperform” rating on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its price target raised by analysts at Barclays PLC from $295.00 to $329.00. They now have an “overweight” rating on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its price target raised by analysts at Raymond James from $275.00 to $298.00. They now have an “outperform” rating on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its price target raised by analysts at Canaccord Genuity Group Inc. from $366.00 to $384.00. They now have a “buy” rating on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
• 11/1/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $300.00 price target on the stock.
• 10/21/2024 – Alnylam Pharmaceuticals had its price target raised by analysts at TD Cowen from $282.00 to $371.00. They now have a “buy” rating on the stock.
• 10/18/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
• 10/16/2024 – Alnylam Pharmaceuticals is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $305.00 price target on the stock.
• 10/14/2024 – Alnylam Pharmaceuticals had its price target raised by analysts at Bank of America Co. from $307.00 to $314.00. They now have a “buy” rating on the stock.
• 10/11/2024 – Alnylam Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $220.00 price target on the stock.
• 10/11/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $300.00 price target on the stock.
• 10/10/2024 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
• 10/10/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
• 9/19/2024 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.

Alnylam Pharmaceuticals Stock Down 1.6 %

ALNY stock opened at $264.60 on Thursday. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The company’s 50 day simple moving average is $275.05 and its 200-day simple moving average is $233.51. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The firm has a market capitalization of $34.13 billion, a PE ratio of -100.99 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. The business’s revenue was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.15 EPS. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $20,563,480. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC grew its holdings in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $26,000. Huntington National Bank increased its position in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new position in Alnylam Pharmaceuticals during the third quarter worth approximately $29,000. Finally, Altitude Crest Partners Inc. purchased a new position in Alnylam Pharmaceuticals during the first quarter worth approximately $30,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.